Senti Bio Extends Cash Runway to 2026 with Additional $11.5 Million Financing

Senti Bio has raised an additional $11.5 million in financing, bringing the total raised in the round to $47.6 million. The additional funding will extend the company's cash runway guidance into 2026 and will be used to fund the development of its SENTI-202 program and manufacturing ramp-up, as well as other research and development activities. The financing was led by Celadon Partners and included participation from New Enterprise Associates (NEA), Leaps by Bayer, and other institutional and accredited investors.